Expert Review of Endocrinology & Metabolism最新文献

Is a new definition for childhood obesity needed? 儿童肥胖需要一个新的定义吗？

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-10-06 DOI: 10.1080/17446651.2025.2570236

Petur B Juliusson

引用次数: 0

Advances in the genetics of Paget's disease of bone: from pathophysiology, diagnosis to clinical implications. 骨佩吉特病的遗传学进展：从病理生理学、诊断到临床意义。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-30 DOI: 10.1080/17446651.2025.2564667

Laëtitia Michou, Jacques P Brown

{"title":"Advances in the genetics of Paget's disease of bone: from pathophysiology, diagnosis to clinical implications.","authors":"Laëtitia Michou, Jacques P Brown","doi":"10.1080/17446651.2025.2564667","DOIUrl":"10.1080/17446651.2025.2564667","url":null,"abstract":"Introduction: Paget's Disease of Bone (PDB) is a chronic, late-onset skeletal disorder characterized by highly localized regions of increased bone resorption, accompanied by excessive and abnormal new bone formation. Consequently, PDB serves as a crucial model for elucidating the genetic and molecular mechanisms governing both abnormal osteoclast formation and osteoclast-induced osteoblast/osteocyte activities.Areas covered: This narrative review based on the available indexed literature examines the genetics of PDB and its connections with the pathophysiology of the disease, focusing on interactions with bone cells, environmental factors, clinical presentation, and complications.Expert opinion: PDB research highlights the importance of genetic studies, and the need for further research especially in families not linked to SQSTM1 pathogenic variants. Enhancing education for health care professionals is critical, given PDB's rarity and its exclusion from medical curricula, which leads to diagnostic delays and mismanagement. Further exploration of gene-environmental interactions and the role of bone cells in lesion formation remains a priority. Advances in precision medicine may soon allow genetic testing to predict the risk of PDB using polygenic risk scores, leading to targeted prevention strategies. Future treatments may involve SQSTM1 gene inhibitors, such as siRNA, offering a personalized approach to early prevention and management of PDB.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-14"},"PeriodicalIF":2.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized medicine in acromegaly: insights from the ACROFAST clinical trial. 肢端肥大症的个性化医疗：来自ACROFAST临床试验的见解。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-29 DOI: 10.1080/17446651.2025.2561066

Marta Araujo-Castro, Betina Biagetti, Víctor Navas-Moreno, María Bernarda-Iriarte, Rebeca Martínez-Hernández, Elena Valassi, Manel Puig-Domingo, Mónica Marazuela

{"title":"Personalized medicine in acromegaly: insights from the ACROFAST clinical trial.","authors":"Marta Araujo-Castro, Betina Biagetti, Víctor Navas-Moreno, María Bernarda-Iriarte, Rebeca Martínez-Hernández, Elena Valassi, Manel Puig-Domingo, Mónica Marazuela","doi":"10.1080/17446651.2025.2561066","DOIUrl":"https://doi.org/10.1080/17446651.2025.2561066","url":null,"abstract":"Introduction: Personalized medicine has gained importance in the management of acromegaly, driven by advances in tumor classification, molecular profiling, and imaging modalities. This approach leads to achieved biochemical control more frequently and in a shorter time frame when compared to the usual trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drug, which is still currently recommended in most clinical guidelines.Areas covered: In this review, we summarize recent advances in personalized medicine for acromegaly, with a particular focus on predictive markers of surgical and medical treatment response. Moreover, we highlight the perspectives gained from the ACROFAST clinical trial, which has contributed with valuable insights into the clinical implementation of individualized therapeutic strategies.Expert opinion: We consider that the future of research in acromegaly lies in the continued advancement and refinement of personalized medicine approaches. ACROFAST has laid critical groundwork by demonstrating how the combination of predictive biomarkers enhances therapeutic outcomes, improving the rate of biochemical remission and in a shorter follow-up period. In addition, the application of artificial intelligence and machine learning algorithms trained on multiomic and clinical datasets may be useful to improve outcomes and reduce the trial-and-error nature of current pharmacologic management of acromegaly.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-14"},"PeriodicalIF":2.8,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Growth hormone deficiency in Cushing's syndrome: an update on diagnosis and management. 生长激素缺乏症在库欣综合征：诊断和管理的最新进展。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-13 DOI: 10.1080/17446651.2025.2559673

Nicholas A Tritos

{"title":"Growth hormone deficiency in Cushing's syndrome: an update on diagnosis and management.","authors":"Nicholas A Tritos","doi":"10.1080/17446651.2025.2559673","DOIUrl":"https://doi.org/10.1080/17446651.2025.2559673","url":null,"abstract":"Introduction: Endogenous Cushing's syndrome (CS) is associated with substantial morbidity and mortality. Patients in remission may experience many comorbidities, including growth hormone deficiency (GHD).Areas covered: Electronic searches (PubMed) were conducted through July 2025. The published data largely pertain to patients with Cushing's disease (CS caused by a pituitary tumor). This article reviews the epidemiology of GHD in patients with CS in remission, underlying mechanisms, and clinical manifestations. The diagnosis of GHD is discussed along with data on the effectiveness and safety of growth hormone replacement.Expert opinion: GHD is common in patients with active CS and may persist among patients in remission. In children, decreased linear growth is prevalent. In adults in remission, GHD has been associated with a higher prevalence of cardiometabolic burden (hypertension, diabetes mellitus, cardiovascular and cerebrovascular disease), decreased muscle strength, lower bone mineral density and increased prevalence of fractures. The diagnosis of GHD generally requires stimulation testing and should only be undertaken in patients in remission. In children with CS in remission, growth hormone replacement improves adult height. In adults, growth hormone replacement may improve quality of life, bone mineral density, muscle strength and dyslipidemia but requires careful monitoring for the possible development of hyperglycemia.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-6"},"PeriodicalIF":2.8,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum asprosin and its association with bone mineral density, oxidative stress, and osteoprotegerin levels in Pakistani women with postmenopausal osteoporosis. 巴基斯坦绝经后骨质疏松症妇女血清asprosin及其与骨密度、氧化应激和骨保护素水平的关系

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-01 Epub Date: 2025-05-31 DOI: 10.1080/17446651.2025.2510595

Sampana Fatima, Muhammad Abrar, Adeela Shahid, Hira Moin, Sadaf Majeed

{"title":"Serum asprosin and its association with bone mineral density, oxidative stress, and osteoprotegerin levels in Pakistani women with postmenopausal osteoporosis.","authors":"Sampana Fatima, Muhammad Abrar, Adeela Shahid, Hira Moin, Sadaf Majeed","doi":"10.1080/17446651.2025.2510595","DOIUrl":"10.1080/17446651.2025.2510595","url":null,"abstract":"Objectives: Raised asprosin may be related to the development of postmenopausal osteoporosis. This study aimed to determine the role of asprosin in oxidative stress in postmenopausal osteoporosis and its relation with estrogen, osteoprotegerin (OPG), and bone mineral density (BMD).Methods: A case-control study included 80 women, aged 42-65, presenting at Shalamar Hospital, Lahore, Pakistan. Informed consent was taken, and single blinding was done. Demographic details and a bone mineral density scan were done. Three ml of venous blood sample was taken to measure asprosin, glutathione (GSH), osteoprotegerin, and estrogen levels.Results: Women with osteoporosis had significantly higher levels of serum asprosin and lower levels of OPG than those without osteoporosis. (p < 0.05) Asprosin was negatively correlated with BMD, OPG, and GSH, and positively with body mass index (p < 0.05). The cutoff value of serum asprosin for screening postmenopausal osteoporosis by area under the curve was > 27.4 ng/ml with a sensitivity of 75% and a 1-specificity of 14%.Conclusion: Higher serum asprosin and oxidative stress biomarkers are related to decreased bone mineral density in postmenopausal women. Asprosin may be used as a potential biomarker for early screening of postmenopausal osteoporosis. Small sample size and observational study design were the key limitations of this study.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"427-439"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies. 将多囊卵巢综合征重新定义为肥胖的并发症：以肠促胰岛素为基础的治疗的演变作用。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-01 DOI: 10.1080/17446651.2025.2554668

Mojca Jensterle, Andrej Janez

引用次数: 0

Association of thyroid function within the normal range with glycemic control and cardiovascular risk factors in type 1 diabetes. 1型糖尿病患者正常范围内甲状腺功能与血糖控制及心血管危险因素的关系

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-01 Epub Date: 2025-07-15 DOI: 10.1080/17446651.2025.2532560

Mariana Lourenço, Ana Rita Leite, Patrícia Ferreira, Inês Meira, João Menino, Ana Margarida Lopes, Joana Lagoa, Beatriz Viveiros, Maria João Barbosa, Sílvia Santos Monteiro, Joana Queirós, João Sérgio Neves, Celestino Neves

{"title":"Association of thyroid function within the normal range with glycemic control and cardiovascular risk factors in type 1 diabetes.","authors":"Mariana Lourenço, Ana Rita Leite, Patrícia Ferreira, Inês Meira, João Menino, Ana Margarida Lopes, Joana Lagoa, Beatriz Viveiros, Maria João Barbosa, Sílvia Santos Monteiro, Joana Queirós, João Sérgio Neves, Celestino Neves","doi":"10.1080/17446651.2025.2532560","DOIUrl":"10.1080/17446651.2025.2532560","url":null,"abstract":"Background: Thyroid hormone (TH) variations, even within the normal range, influence cardiometabolic health. In type 1 diabetes (T1D), optimizing glycemic control and cardiovascular risk is crucial to prevent complications. We aim to explore the association of TH within normal range with cardiometabolic profile in T1D.Research design and methods: Cross-sectional analysis including adult patients with T1D followed at our Endocrinology Department between 2022-2024. We excluded patients with TSH or fT4 outside the reference range. Associations between TH (TSH, fT4, fT3 and fT3/fT4 ratio) and glycemic, anthropometric, and cardiometabolic parameters, were evaluated using linear regression models unadjusted and adjusted for relevant variables. Restricted cubic splines between TH and glycemic control parameters were performed to assess non-linear associations.Results: We included 296 patients (median age 35 years, 42.6% female). Patients with mid-range TSH had better glycemic control, with higher time in range and a lower time above range. Waist circumference and body mass index were negatively associated with fT4, and positively with fT3 and fT3/fT4 ratio. Estimated glomerular filtration rate was negatively associated with TSH and fT4, and positively with fT3 and fT3/fT4.Conclusions: Variations in TH within the normal range were associated with glycemic control and cardiovascular risk factors in T1D.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"415-425"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How do we balance metabolic surgery and emerging incretin-based medical therapies for type 2 diabetes? 我们如何平衡代谢手术和新兴的以肠促胰岛素为基础的2型糖尿病药物治疗？

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-01 Epub Date: 2025-07-07 DOI: 10.1080/17446651.2025.2529386

Hamayle Saeed, Mary Elizabeth Patti

引用次数: 0

Prediabetes phenotypes: can aetiology and risk profile guide lifestyle strategies for diabetes prevention? 糖尿病前期表型：病因学和风险概况可以指导糖尿病预防的生活方式策略吗？

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-01 Epub Date: 2025-07-12 DOI: 10.1080/17446651.2025.2532559

Sally D Poppitt, Jennifer Miles-Chan, Marta P Silvestre

{"title":"Prediabetes phenotypes: can aetiology and risk profile guide lifestyle strategies for diabetes prevention?","authors":"Sally D Poppitt, Jennifer Miles-Chan, Marta P Silvestre","doi":"10.1080/17446651.2025.2532559","DOIUrl":"10.1080/17446651.2025.2532559","url":null,"abstract":"Introduction: Type 2 diabetes (T2D) continues to worsen globally alongside rise in obesity. Asymptomatic dysglycaemia, which precedes T2D, provides opportunities to identify those at risk and target prevention but prediabetes is highly variable. Not all with overweight develop dysglycaemia and not all with dysglycaemia are overweight. Important is the deposition of ectopic lipids in the pancreas, liver, and muscle. With no international definition, several prediabetes phenotypes exist, each based on one or more components of fasting glucose, postprandial glucose and/or HbA1c.Areas covered: We address variability in prediabetes phenotype and absence of a universal definition. With four main phenotypes based on the various glycemic definitions, it is likely they have different etiologies, risk profiles, timelines to T2D, and response to lifestyle intervention. Who do we treat, and when? Do we treat early or late? What is the optimum diet for T2D prevention? Do different phenotypes require different prevention approaches?Expert opinion: Personalized lifestyle, or phenotype-specific treatments, are likely to be more successful for T2D prevention than a 'one-size-fits-all' approach. Artificial intelligence (AI) methods, currently in their infancy, are expected to revolutionize personalized nutrition with integration of 'big data' better characterizing and predicting prediabetes phenotype, and phenotype-specific response to diet and lifestyle interventions.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"361-371"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential metabolic responses to very-low calorie diets in individuals with, and without type 2 diabetes: a review. 2型糖尿病患者和非2型糖尿病患者对极低卡路里饮食的代谢反应差异综述

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-09-01 Epub Date: 2025-07-04 DOI: 10.1080/17446651.2025.2527791

Oluwaseun Anyiam, Iskandar Idris

{"title":"Differential metabolic responses to very-low calorie diets in individuals with, and without type 2 diabetes: a review.","authors":"Oluwaseun Anyiam, Iskandar Idris","doi":"10.1080/17446651.2025.2527791","DOIUrl":"10.1080/17446651.2025.2527791","url":null,"abstract":"Introduction: Very-low calorie-diets (VLCD) are becoming increasingly popular for managing overweight, obesity and type 2 diabetes (T2D). Beta-cell dysfunction and insulin resistance (IR) is present in individuals living with overweight and obesity, with or without T2D. Results from metabolic studies investigating the effect of VLCD on beta cell function (BCF) and IR are inconsistent, despite the well-documented effects on weight and glycaemic control.Areas covered: We undertook a narrative review of studies identified from PubMed and their associated reference lists, examining apparent discrepancies in the literature on this topic. Evidence broadly suggests a positive impact of VLCD, although the outcome being measured, and method of assessment could influence the observed effect. The VLCD duration is a critical factor, as longer-term interventions are required to consistently demonstrate improvements in BCF and peripheral IR. Hepatic IR appears to be particularly responsive to short-term caloric restriction.Expert opinion: When interpreting metabolic results of VLCD intervention studies, particular attention must be paid to the selected method of assessing BCF and IR. Improvement in BCF exhibits significant heterogeneity, possibly related to individual participant's clinical characteristics. Beneficial effects on hepatic IR occur in the early stage of VCLD intervention, preceding changes in peripheral IR and BCF.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"373-384"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0